Eyes focused on the stock price of’Punglim Pharmatech’…

[사진=아주경제 DB]

As President Moon Jae-in inspected Poonglim Pharmatech’s LDS syringe production process on the 18th, attention is being drawn to Poonglim Pharmatech’s stock price.

President Moon inspected the production process of Poonglim Pharmatech’s LDS syringe located in Gunsan, Jeollabuk-do, and said, “The world’s attention is focused on the minimal residual syringe that can inoculate one more person per vaccine.” Yanghaeng and Doowon Meditech have shown the excellence of K-quarantine once again following the diagnostic kit.”

The special syringe made by Poonglim Pharmatech is a syringe for Corona 19 vaccine with the minimum injection residual quantity (LDS) technology applied, and it has the effect of increasing the vaccine production by 20% by significantly reducing the loss of the remaining injection amount.

This syringe is designed to be able to inject more than 6 times per bottle, unlike regular syringes that can inject up to 5 times per bottle of Corona 19 vaccine.

Currently, Poonglim Pharmatech’s special syringes can produce more than 10 million units per month. Japan has ordered 75 million units, and orders are pouring in from the United States, Europe, the Middle East, and Southeast Asia.

Poonglim Pharmatech is currently applying for domestic technology patents and design patents, and is preparing to apply for international patents in the United States and the European Union.

Meanwhile, Poonglim Pharmatech is a privately held company and cannot be bought in the stock market.

Keys related to vaccine syringes include Medipost, Samsung Pharmaceutical, Sewoon Medical, Shinshin Pharmaceutical, Raphas, Huons, Innotherapy, Sanga Front Tech, and Seorin Bio.